Business Description
Benitec Biopharma Inc
NAICS : 325412
SIC : 2834
ISIN : US0820533075
Share Class Description:
BNTC: Ordinary SharesCompare
Compare
Traded in other countries / regions
BNTC.USABLT.AustraliaBJ9.Germany IPO Date
2012-07-11Description
Benitec Biopharma Inc is a biotechnology company developing a proprietary therapeutic technology platform that combines RNA interference with gene therapy for providing sustained, long-lasting silencing of disease-causing genes from a single administration. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The company is developing product candidates in chronic and life-threatening human disease areas including Orphan disease: Oculopharyngeal Muscular Dystrophy (OPMD) and Infectious disease: Hepatitis B Virus (HBV). BB-301 is currently under development by the group; it is designed to slow, or halt, the disease progression.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 48.17 | |||||
| Equity-to-Asset | 0.72 | |||||
| Debt-to-Equity | 0.03 | |||||
| Debt-to-EBITDA | -0.02 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | -12.54 | |||||
| Beneish M-Score | -4.14 | |||||
| WACC vs ROIC | ||||||
Growth Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -17.3 | |||||
| 3-Year EBITDA Growth Rate | -21 | |||||
| 3-Year EPS without NRI Growth Rate | -19.9 | |||||
| 3-Year FCF Growth Rate | -20 | |||||
| 3-Year Book Growth Rate | -90.8 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 67.83 | |||||
| 9-Day RSI | 66.15 | |||||
| 14-Day RSI | 65.16 | |||||
| 6-1 Month Momentum % | 53.67 | |||||
| 12-1 Month Momentum % | 53.57 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.62 | |||||
| Quick Ratio | 3.62 | |||||
| Cash Ratio | 3.55 | |||||
| Days Sales Outstanding | 341.07 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -193.4 | |||||
| Shareholder Yield % | -171.44 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 272.13 | |||||
| Operating Margin % | -35560.66 | |||||
| Net Margin % | -35754.1 | |||||
| FCF Margin % | -29616.39 | |||||
| ROE % | -210.98 | |||||
| ROA % | -149.39 | |||||
| ROIC % | -1477.46 | |||||
| ROC (Joel Greenblatt) % | -3537.35 | |||||
| ROCE % | -205.13 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 200.81 | |||||
| PB Ratio | 1.24 | |||||
| Price-to-Tangible-Book | 1.24 | |||||
| EV-to-EBIT | 0.09 | |||||
| EV-to-EBITDA | 0.1 | |||||
| EV-to-Forward-EBITDA | -0.02 | |||||
| EV-to-Revenue | -33.82 | |||||
| EV-to-FCF | 0.11 | |||||
| Price-to-Net-Current-Asset-Value | 1.29 | |||||
| Price-to-Net-Cash | 1.33 | |||||
| Earnings Yield (Greenblatt) % | 1111.11 | |||||
| FCF Yield % | -93.79 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:BNTC
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Benitec Biopharma Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0.061 | ||
| EPS (TTM) ($) | -10.952 | ||
| Beta | 0.69 | ||
| Volatility % | 85.41 | ||
| 14-Day RSI | 65.16 | ||
| 14-Day ATR ($) | 0.557417 | ||
| 20-Day SMA ($) | 5.94157 | ||
| 12-1 Month Momentum % | 53.57 | ||
| 52-Week Range ($) | 1.86 - 9.01 | ||
| Shares Outstanding (Mil) | 2.59 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Benitec Biopharma Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Benitec Biopharma Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Benitec Biopharma Inc Frequently Asked Questions
What is Benitec Biopharma Inc(BNTC)'s stock price today?
The current price of BNTC is $7.43. The 52 week high of BNTC is $9.01 and 52 week low is $1.86.
When is next earnings date of Benitec Biopharma Inc(BNTC)?
The next earnings date of Benitec Biopharma Inc(BNTC) is .
Does Benitec Biopharma Inc(BNTC) pay dividends? If so, how much?
Benitec Biopharma Inc(BNTC) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers